Tykerb
Tykerb is the brand name for lapatinib, an oral small-molecule tyrosine kinase inhibitor developed for the treatment of HER2-positive breast cancer. It targets the kinase activity of two receptors, EGFR (HER1) and HER2, reducing signaling pathways that promote tumor cell growth and survival.
Indications for lapatinib include treatment of advanced or metastatic HER2-overexpressing breast cancer in combination with the
Mechanism of action involves reversible inhibition of the intracellular tyrosine kinases of both EGFR and HER2,
Administration and dosing are oral, typically once daily. Lapatinib should be taken on an empty stomach, at
Common adverse effects include diarrhea, rash, nausea, fatigue, and mucositis. Hepatotoxicity with elevated liver enzymes has
Tykerb received FDA approval in 2007 and is marketed by GlaxoSmithKline for HER2-positive breast cancer.